The study of QRX003 Lotion in subjects with Netherton Syndrome

illustrative image

The company Quoin Pharmaceuticals is commencing recruitment for the clinical trial of the Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome.

The trial officially began on the June 23, 2022 and is planned to complete on June 2023.

This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% in subjects with Netherton Syndrome (NS) in comparison to vehicle

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05521438.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Upcoming Clinical Trials

The study of QRX003 Lotion in subjects with Netherton Syndrome

All jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe